ACD/Labs joins MDL Isentris Alliance
San Ramon, CA and Toronto, Canada, May 10, 2006 - Advanced Chemistry Development, Inc. (ACD/Labs) has joined a growing community of informatics companies working with Elsevier MDL to offer scientists better integrated informatics solutions for managing pharmaceutical, biotechnology and other life sciences research. ACD/Labs, a longtime collaborator with Elsevier MDL, joins the rapidly expanding MDL® Isentris® Alliance as a preferred partner and will provide connections between its products and the new-generation MDL Isentris platform.
Antony Williams, VP and Chief Science Officer for ACD/Labs said: “ACD/Labs recognizes that members of the scientific community rely on a variety of informatics tools and technologies to meet specialized needs. For many years we have worked with Elsevier MDL to provide integration between our powerful predictive tools and analytical data management solutions and MDL® ISIS technology. Now we can extend that legacy of cooperation and offer integrated solutions for researchers using the new MDL Isentris platform.”
“By making it easier for scientists to conduct research—accessing the data they need using applications that work together—the informatics companies in the MDL Isentris Alliance are offering R&D organizations a path to improved productivity,” said Elsevier MDL Senior Vice President Vikki Rehn, Framework Development. “As major pharmaceutical companies adopt the new-generation MDL Isentris platform, they benefit immediately from collaboration that permits rapid integration of specialty applications into comprehensive research information systems. For years, our partnership with ACD/Labs has brought important value to mutual customers. By joining the Isentris Alliance, ACD/Labs increases the value to researchers using Isentris.”
ACD/Labs joins a group of leading software and consulting companies from around the world (including Spotfire, Tripos, InfoChem, InforSense, Klee, Aston, DeltaSoft and Symyx) working with Elsevier MDL to create informatics solutions that combine MDL Isentris technology and specialized vendors’ offerings. MDL Isentris is an open technology, tiered informatics platform for integrating data, workflow applications and business processes.
Initial integration between ACD/Labs and Elsevier MDL will focus on ACD/Name software and the Isentris-based MDL® Draw chemical representation tool and MDL® Notebook application. The integration will be extended later to enable researchers to simplify everyday chemistry-related tasks, including accessing chemical property calculators and name/structure converters.
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services.
Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.
Advanced Chemistry Development, Inc., (ACD/Labs) is a chemistry software company offering solutions that truly integrate chemical structures with analytical chemistry information to produce ChemAnalytics®. ACD/Labs creates innovative software packages that aid chemical research scientists worldwide with spectroscopic validation of structures, elucidation of unknown substances, chromatographic separation, medicinal chemistry, preformulation of novel drug agents, systematic nomenclature generation, and chemical patenting and publication. Combined, ACD/Labs' solutions create an analytical informatics system that provides dramatic feed-forward effects on the chemical and pharmaceutical research process. Founded in 1993, and headquartered in Toronto, Canada, ACD/Labs employs a team of over 100 dedicated individuals whose continual efforts carry ACD/Labs' innovative technologies into pharmaceutical, biotech, chemical, and materials companies throughout the world. Information about Advanced Chemistry Development and its products can be found at www.acdlabs.com.
MDL and Isentris are registered trademarks of MDL Information Systems, Inc. (‘Elsevier MDL’) in the United States. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Antony J. Williams, Ph.D.
Vice President and Chief Science Officer
Advanced Chemistry Development, Inc. (ACD/Labs) US Office
Phone: (919) 341-8375
Dr. Phil McHale
VP, Market and Corporate Communications
Phone: (510) 357-2222 ext. 3541